Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II obinutuzumab monotherapy in rituximab-refractory follicular lymphoma
NL-OMON24035Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of obinutuzumab in follicular lymphoma (FL), sponsored by Vrije University Medical Center. Primary endpoint: Overall response rate. Started Aug 2015; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON24035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24035.